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Received July 25, 2014; accepted November 14, 2014AbstractBackground: To analyze the pregnancy complications and pregnancy outcome relating to the disease activity of systemic lupus erythematosus
before conception and during pregnancy.
Methods: Seventy-two pregnancies were collected in a single tertiary medical center within a 5-year period. Twelve pregnancies were terminated
due to various causes in the first half of pregnancy. Analysis of pregnancy complications and pregnancy outcome relating to the lupus activity
before conception and during pregnancy was made among the remaining 60 pregnancies with gestational length > 26 weeks. The assessment of
lupus activity was based on the routine monitoring, including urine routine, white blood cell count, hemoglobin and platelet count, erythrocyte
sediment rate, serum titers of C3, C4, and double-stranded DNA. Monitoring of renal function with daily urinary protein loss and clearance rate
of creatinine was needed when worsened nephropathy was suspected.
Results: The etiologies of the terminated pregnancies were deteriorated nephropathy (6 cases), involvement of central nervous system (1 case),
unwanted pregnancy due to drug exposure (3 cases), and two early intrauterine fetal deaths (both during the 23rd week of gestation). Pregnancy
complications were related to the lupus activity before conception [odds ratio ¼ 0.238, 95% confidence interval (CI) ¼ 0.073, 0.778, p ¼ 0.014]
and during pregnancy (odds ratio ¼ 0.153, 95% CI ¼ 0.031, 0.754, p ¼ 0.012). Meanwhile, pregnancy outcome significantly related to the lupus
activity of the preconception period and during pregnancy. The gestational length was significantly longer in the pregnancies with remitted lupus
activity either before conception (38.2 ± 1.6 weeks vs. 36.3 ± 3.4 weeks, p ¼ 0.011 and 95% CI ¼ 3.454, 0.478) or during pregnancy
(38.2 ± 1.6 weeks vs. 35.2 ± 3.8 weeks, p ¼ 0.005 and with 95% CI ¼ 4.988, 1.005). Significant relationships were also found between
newborn birth weights and lupus activity preconceptionally (2940 ± 389 g vs. 2448 ± 674 g, p ¼ 0.002 and 95% CI ¼ 792, 192) and after
having conceived (2960 ± 383 g vs. 2136 ± 585 g, p < 0.001 and 95% CI ¼ 1081, 568). Multivariate analysis showed that lupus remission
during pregnancy was correlated with a significantly longer gestation, since pregnant women with active lupus had a three-fold greater risk of
preterm deliveries (hazard ratio ¼ 3.022, 95% CI ¼ 1.261, 7.242) compared with pregnant women without active lupus.
Conclusion: In order to reduce the incidence of pregnancy complication, especially preterm delivery, and to gain good pregnancy outcome, good
preparation before conception and good control of the disease during pregnancy are mandatory.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Systemic lupus erythematosus (SLE) is the most common
immunologic disorder in women of reproductive age. It pro-
duces specific symptoms and signs of involved organs.
Fertility is not affected when the disease activity is
controlled.1 Stable preconceptional lupus activity is recom-
mended for planning pregnancy.2 However, some patients
become pregnant unexpectedly without remission. Termina-
tion of pregnancy may not be needed if there were neither
severe lupus nephropathy nor involvement of central nervous
system at the time of conception.
Many complications, such as abortion, fetal loss, preterm
birth, pregnancy-induced hypertension, preeclampsia super-
imposed on chronic hypertension, intrauterine fetal distress,
and fetal growth restriction make pregnancies with lupus very
complicated, especially in those cases who were not well
prepared for conception.3e5 However, the correlation between
pregnancy outcome and preconceptional lupus activity was
still questionable for lack of convincing analysis. In this study,
statistical analyses of the pregnancy complications and preg-
nancy outcomes associated with the lupus activity before
conception and during pregnancy was done only on those
cases that gave birth after completing 26 weeks of gestation.
2. Methods
From July 2008 to June 2013, all pregnant women suffering
from SLE who gave birth to their babies in a single tertiary
center hospital (Taipei Veterans General Hospital, Taipei,
Taiwan) were enrolled in this study. With permits of the pa-
tients, the following data were collected: age, gravidity, parity,
age at the onset of disease, duration of disease, lupus activity
before and after conception, complications during pregnancy,
newborn birth weight, gestational age at delivery, and medi-
cations given before conception and during pregnancy. All the
women enrolled were followed-up regularly at the prenatal
clinic and at least once per month by a rheumatologist.
Intensive care was given when the disease activity was re-
lapsing (flare-up) or becoming worse.
Other than clinical symptoms, the assessment of the lupus
activity was based on the routine monitors, including urinal-
ysis, white blood cell count, hemoglobin level, platelet count,
erythrocyte sediment rate, and serum levels of C3, C4, and
double-stranded DNA. Monitoring renal function with daily
urinary protein loss and measurement of creatinine clearance
as well as serum blood urea nitrogen and creatinine were
needed, especially when exacerbated nephropathy was sus-
pected. If the above measurements were all within normal
limits, the patient's lupus activity was defined as “stable” or “in
remission”. Lupus activity was defined as “relapsed” or
“without remission” when some or all of the above measure-
ments went out of normal limits in those cases who were
originally with remission. It was defined as “deteriorated” or
“exacerbated” when some or all of the above measurements
were worsening in those cases that were originally not
remitted.Pregnancy complications included threatened abortion,
preterm labor, preterm delivery, gestational diabetes mellitus
(GDM), pregnancy-induced hypertension, preeclampsia,
chronic hypertension, intrauterine chronic fetal distress, in-
trauterine growth restriction (IUGR), and perinatal loss
(including intrauterine fetal death and neonatal loss).
The data were analyzed with independent-sample t test
between continuous variables, and with c2 test between
noncontinuous variables. Survival (preterm delivery, defined
as delivery occurring at < 37 weeks of gestation) was deter-
mined on the basis of parameters and patient outcomes. Esti-
mates of the proportion of overall survival (OS) were
calculated by the KaplaneMeier procedure, and differences in
survival were evaluated via log-rank test. Covariance analysis
and the hierarchic c2 test were used to control for potential
confounding factors in the comparison of patients' character-
istics and risk factors. The log-rank test, hazard ratio (HR),
and 95% confidence interval (CI) of preterm births from
pregnant women with SLE were calculated via Cox propor-
tional hazards model with univariate and multivariate analysis
of OS. SPSS version 20 (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. Statistical significance was
determined by unpaired two-tailed Student t test using a
pooled estimator of variance, and was defined as p < 0.05. The
study project was approved by the Institutional Review Board
of Taipei Veterans General Hospital (IRB No. 2011-12-
0171B#1).
3. Results
Sixty-five women with SLE had 72 pregnancies during the
study period from July 2008 to June 2013. Twelve pregnancies
in 12 patients were excluded due to termination for various
causes in the first half of pregnancy. Six of them were
terminated due to deteriorated lupus nephropathy. One of these
six patients died thereafter due to poor response to immuno-
suppressive treatment. Of the remaining six pregnancies, one
was terminated due to the involvement of the central nervous
system by SLE; three were terminated because of drug
exposure; and the remaining two were terminated due to in-
trauterine fetal death. One fetal death resulted from twisted
cord found during the 23rd week of gestation, and the other
one was the consequence of deteriorated nephropathy during
the 23rd week of gestation.
The remaining 60 pregnancies in 55 women who gave birth
to their newborns after 26 completed weeks' gestation were
divided into two groups based on the preconceptional lupus
activity, with remission and without remission. There were 34
(56.7%) cases with remission, and the remaining 26 (43.3%)
cases were not remitted preconceptionally. The same work
was done on the base of lupus activity during pregnancy. At
delivery, the remission group had 43 cases and the remaining
17 cases were without remission. The total number of de-
liveries during the same period of time was 9419. The inci-
dence of delivery with SLE was 0.64% (60/9419).
Mean age of the patients of the 60 pregnancies was
29.7 ± 4.8 years old, with range between 20 years and 43
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parity was 1.7 ± 0.8, range 1e3. Sixty-one (1 set of twins)
babies were born, with one intrauterine fetal death at 35
weeks' gestation. The mean birth weight of newborns was
2727 ± 581 g, range 890e3885 g. The mean gestational age of
birth was 37.4 ± 2.6 weeks, range 26e41 weeks. The mean
age of onset of SLE was 24.2 ± 5.6 years, range 12e37 years.
The mean duration of the disease was 5.4 ± 3.7 years, range <
1e17 years (Table 1).3.1. Lupus activity during pregnancyFour of the 34 originally preconceptional remission cases
relapsed during pregnancy. Three of them were diagnosed dur-
ing the first trimester, the remaining one relapsed during the third
trimester. In the first trimester, one of them went into remission
again after adjuvant plaquenil was given. Two of the 26 origi-
nally preconceptional without remission cases went into
remission during pregnancy without changing treatment regi-
mens. Ten of the remaining 24 pregnancies went into remission
after treatment regimens were changed. Of the relapsed or
deteriorated cases, 17 pregnancies were found during the first
trimester, eight in the second trimester, and two in the third
trimester. Consequently, there were 43 pregnancies having
remission of lupus activity at delivery, and 17 without remission.3.2. Lupus activity and pregnancy complicationsIn the preconceptional remission group (n ¼ 34), four cases
(11.8%) suffered from preterm birth. Pregnancy-induced hy-
pertension was found in six (17.6%) cases. Three (8.8%) cases
experienced threatened abortion. Placental abruption was
found in one pregnancy. Gestational diabetes mellitus was
disclosed in three (8.8%) cases. Seventeen (50%) pregnancies
were free from complications. By contrast, in the group of
pregnancies without remission preconceptionally (n ¼ 26),
only five (19.2%) pregnancies were free from complications
during gestational periods. Six (23.1%) patients suffered from
pregnancy-induced hypertension. Threatened abortion was
found in six (23.1%) cases. Nine (34.6%) pregnancies ended in
preterm birth, four (15.4%) were with IUGR, three (11.5%)
were with renal failure, three (11.5%) were with chronic hy-
pertension, one (3.8%) was with intrauterine fetal distress, two
(7.7%) were with placental abruption, and one (3.8%) wasTable 1
Patient characteristics.
Mean ± SD Range
Total no. of pregnancies (n ¼ 60)
Age (y) 29.7 ± 4.8 20e43
Gravidity 2.6 ± 1.4 1e6
Parity 1.7 ± 0.8 1e3
Birth weight (g) 2727 ± 581 890e3885
Gestational age at birth (wk) 37.4 ± 2.7 26e41
Age at onset of SLE (y) 24.2 ± 5.6 12e37
Duration of disease (y) 5.4 ± 3.7 0e17
SD ¼ standard deviation; SLE ¼ systemic lupus erythematosus.with intrauterine fetal loss. Significant correlations were found
between preconceptional lupus activity and pregnancy com-
plications. They were preterm birth [odds ratio (OR) ¼ 0.323,
95% CI ¼ 0.067, 0.942, p ¼ 0.033], chronic hypertension
(OR ¼ 0.404, 95% CI ¼ 0.294, 0.553, p ¼ 0.042), IUGR
(OR ¼ 0.393, 95% CI ¼ 0.284, 0.544, p ¼ 0.018), renal failure
(OR ¼ 0.404, 95% CI ¼ 0.294, 0.553, p ¼ 0.042), and the
incidence of free pregnancy complications (OR ¼ 0.238, 95%
CI ¼ 0.073, 0.778, p ¼ 0.014; Table 2).
In the group of stable lupus activity during pregnancy
(n ¼ 43), 20 (46.5%) pregnancies were free from complica-
tions. Eight (18.6%) cases experienced threatened abortion.
Preterm birth was found in five (11.6%) patients, three (7.0%)
patients were with GDM, pregnancy-induced hypertension in
seven (16.3%), two (4.7%) suffering from placental abruption,
and one (2.3%) was with IUGR. In the group of unstable lupus
activity (n ¼ 17), only two (11.8%) cases were free from
pregnancy complications. Intrauterine fetal death occurred in
one (5.9%) case, one (5.9%) was with threatened abortion,
eight (47.1%) were with preterm birth, five (29.4%) were with
pregnancy-induced hypertension, three (17.6%) were with
IUGR, three (17.6%) were with renal failure, three (17.6%)
were with chronic hypertension, placental abruption in one
pregnancy (5.9%), and one (5.9%) was with intrauterine fetal
distress. Lupus activity was correlated to preterm birth
(OR ¼ 0.148, 95% CI ¼ 0.039, 0.561, p ¼ 0.003), chronic
hypertension (OR ¼ 0.404, 95% CI ¼ 0.294, 0.553,
p ¼ 0.042), renal failure (OR ¼ 0.246, 95% CI ¼ 0.156, 0.387,
p ¼ 0.005), and pregnancy free from complications
(OR ¼ 0.153, 95% CI ¼ 0.031, 0.754, p ¼ 0.012; Table 2).3.3. Pregnancy outcomesBoth newborn birth weight and gestational length were
related to preconceptional lupus activity. The mean birth
weights of the preconceptional remission group and no
remission group were 2940 ± 389 g (range, 2060e3885 g) and
2448 ± 674 g (range, 890e3524 g), respectively. Significant
correlation was found by t test analysis, with p ¼ 0.002 and
95% CI ¼ 792, 192. The mean gestational ages of the two
groups were 38.4 ± 1.6 weeks (range, 34e41 weeks) and
36.3 ± 3.4 weeks (range, 26e41 weeks), respectively. Anal-
ysis with t test showed significant correlation with p ¼ 0.011
and 95% CI ¼ 3.454, 0.478 (Table 3).
Similarly, both newborn birth weight and gestational length
were significantly correlated to lupus activity during preg-
nancy. The mean birth weight of the remission group was
2960 ± 383 g, range 2060e3885 g. In the lupus activity group
without remission, the mean birth weight was 2136 ± 585 g,
range 890e2760 g. By analysis with t test, there was signifi-
cant correlation, with p < 0.001 and 95% CI ¼ 1081, 568.
In the group with remission, mean gestational age was
38.2 ± 1.6 weeks, range 34e41 weeks. The mean gestational
age of the group without remission was 35.2 ± 3.8 weeks,
range 26e40 weeks. There was significant correlation, with
p ¼ 0.005 and 95% CI ¼ 4.988, 1.005, analyzed with t test
(Table 4).
Table 2
Pregnancy complications related to lupus activity.
Complications Preconception During pregnancy
With remission No remission p OR CI With remission No remission p OR CI
TA 3 6 0.125 0.323 0.072, 1.439 8 1 0.214 3.657 0.421, 31.755
Preterm labor 2 6 0.261 2.571 0.474, 13.945 7 1 0.286 3.111 0.353, 27.425
Preterm birth 4 9 0.033 0.252 0.067, 0.942 5 8 0.003 0.148 0.039, 0.561
PIH 6 6 0.602 0.714 0.201, 2.540 7 5 0.252 0.467 0.125, 1.748
Chronic HTN 0 3 0.042 0.404 0.294, 0.553 0 3 0.042 0.404 0.294, 0.553
Placental abruption 1 2 0.403 0.364 0.031, 4.245 2 1 0.844 0.780 0.066, 9.218
GDM 3 0 0.120 0.544 0.429, 0.690 3 0 0.264 0.702 0.592, 0.831
IUGR 0 4 0.018 0.393 0.284, 0.544 1 3 0.032 0.111 0.011, 1.156
Renal failure 0 3 0.042 0.404 0.294, 0.553 0 3 0.005 0.246 0.156, 0.387
Fetal distress 0 1 0.249 0.424 0.315, 0.571 0 1 0.109 0.271 0.178, 0.412
Fetal demise 0 1 0.249 0.424 0.315, 0.571 0 1 0.109 0.271 0.178, 0.412
None 17 5 0.014 0.238 0.073, 0.778 20 2 0.012 0.153 0.031, 0.754
CI ¼ confidence interval; GDM ¼ gestational diabetes mellitus; HTN ¼ hypertension; IUGR ¼ intrauterine fetal growth restriction; OR ¼ odds ratio;
PIH ¼ pregnancy-induced hypertension; TA ¼ threatened abortion.
Table 3
Pregnancy outcomes associated with preconceptional lupus activity.
Preconceptional lupus activity
With remission Without remission p (95% CI)
Patients (n) 34 26
Age (y), mean ± SD 29.3 ± 4.7 (21e38) 30.1 ± 5.1 (20e43) 0.555 (1.784, 3.291)
Gravidity 2.7 ± 1.5 (1e6) 2.5 ± 1.4 (1e6) 0.470 (1.027, 0.480)
Parity 1.7 ± 0.8 (1e3) 1.7 ± 0.8 (1e3) 0.909 (0.418, 0.373)
Mean BW (g) 2940 ± 389 (2060e3885) 2448 ± 674 (890e3524) 0.002 (792, 192)*
Mean GA (wk) 38.2 ± 1.6 (34e41) 36.3 ± 3.4 (26e41) 0.011 (3.454, 0.478)*
Age at onset (y) 23.4 ± 5.7 (12e35) 25.1 ± 5.3 (16e37) 0.243 (1.188, 4.595)
Duration of SLE (y) 5.8 ± 3.4 (1e17) 4.8 ± 4.1 (0e14) 0.304 (2.947, 0.936)
* t test.
BW ¼ birth weight; GA ¼ gestational age; SD ¼ standard deviation; SLE ¼ systemic lupus erythematosus.
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gestation)Since preterm delivery might be the most important single
factor to predict fetal outcome, we used 37 gestational weeks
as a cutoff value to investigate the risk factors in women with
SLE. Univariate analysis showed that only remission of SLE
during pregnancy was significant, since the women without
remission of SLE during pregnancy had a higher risk of pre-
term delivery (HR ¼ 2.335, 95% CI ¼ 1.124, 4.847).
Furthermore, multivariate analysis confirmed that remission ofTable 4
Pregnancy outcomes associated with lupus activity during pregnancy.
With remission
Patients (n) 43
Age (y), mean ± SD 29.7 ± 4.7 (21e40)
Gravidity 2.7 ± 1.5 (1e6)
Parity 1.7 ± 0.8 (1e3)
Mean BW (g) 2960 ± 383 (2060e3885)
Mean GA (wk) 38.2 ± 1.6 (34e41)
Age at onset (y) 23.9 ± 5.3 (12e35)
Duration of SLE (y) 5.6 ± 3.7 (0e17)
* t test.
BW ¼ birth weight; GA ¼ gestational age; SD ¼ standard deviation; SLE ¼ systSLE during pregnancy was the single most important predictor
of preterm delivery. Women without remission of SLE during
pregnancy had a three-fold risk of preterm deliveries (<37
weeks of gestation) compared to those women with remission
(HR ¼ 3.022, 95% CI ¼ 1.261, 7.242; Table 5).
4. Discussion
Flaring up of lupus during pregnancy is common and oc-
curs significantly more frequently than does flare up in
nonpregnant SLE patients or in the same patients afterLupus activity during pregnancy
Without remission p (95% CI)
17
29.5 ± 5.3 (20e43) 0.888 (3.049, 2.548)
2.4 ± 1.4 (1e5) 0.493 (1.115, 0.543)
1.7 ± 0.7 (1e3) 0.802 (0.380, 0.489)
2136 ± 585 (890e2760) <0.001 (1081, 568)*
35.2 ± 3.8 (26e40) 0.005 (4.988, 1.005)*
24.7 ± 6.3 (16e37) 0.631 (2.435, 3.987)
4.7 ± 3.9 (0e14) 0.377 (3.091, 1.188)
emic lupus erythematosus.
Table 5
Univariate and multivariate Cox regression analyses for the risk of preterm
delivery.
Characteristics Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age (y)
<34 1 (Ref) 1 (Ref)
34 1.244 (0.525e2.949) 0.620 1.773 (0.624e5.033) 0.282
Gravidity
<2 1 (Ref) 1 (Ref)
2 0.941 (0.481e1.841) 0.859 0.769 (0.320e1.853) 0.559
Parity
No 1 (Ref) 1 (Ref)
Yes 1.214 (0.668e2.207) 0.524 1.377 (0.604e3.142) 0.447
Age at onset (y)
<24 1 (Ref) 1 (Ref)
24 0.802 (0.446e1.441) 0.460 0.466 (0.196e1.109) 0.084
Duration of SLE (y)
<5 1 (Ref) 1 (Ref)








1.247 (0.675e2.303) 0.480 1.212 (0.571e2.574) 0.617
Lupus activity during pregnancy
With remission
(n ¼ 43)




2.335 (1.124e4.847) 0.023 3.022 (1.261e7.242) 0.013
Preterm labor ¼ delivery at < 37 weeks of gestational age; SLE ¼ systemic
lupus erythematosus.
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lupus flare-up during pregnancy and to get good pregnancy
outcome, remission of SLE for 6 months before conception
was recommended for planned pregnancy.7 However, fertility
was usually not affected unless the patient was critically ill
with SLE. Some of the patients conceived without planning or
good control of the disease. Consequently, obstetric compli-
cations and poor pregnancy outcomes were commonly seen in
those cases with active lupus activity during pregnancies.
Flare-up of lupus activity was foundmostly during the second
trimester and the postpartum period.8 It was supposed that
medication was discontinued during the first trimester and
resulted in the flare-up during the second trimester. However,
lupus flare-up could happen in all three trimesters,9 although low
probability in the third trimester due to a lower humoral immune
response resulted from the lack of estrogen increment was
found.10 In our study, flare-upsweremostly found during the first
trimester, especially in those cases of the preconceptional non-
remission group, and lowest during the third trimester. Cessation
or reduction of medication during the first trimester due to
gastrointestinal disturbance, rejection or reluctance to take
medicines to avoid fetal injury might be the most probable fac-
tors of flare-up. In this study, medication was adjusted as soon as
possible whenever relapsed or deteriorated lupus activity was
found. A large portion of these flare-up patients experienced
remission after treatment regimen was revised, andconsequently, significant good pregnancy outcomes were ob-
tained, which was not the same as the findings of Petri et al.6
Other than nephropathy with heavy protein loss or low
clearance rate of creatinine, in patients complicated with
preeclampsia, the assessment of severity was based upon the
changes of the following, including platelet count, liver, renal
functions, coagulation tests (activated partial thromboplastin
time, prothrombin time, fibrinogen, fibrin degradation prod-
ucts, protamine sulfate test), fetal growth rate, uteroplacental
function test, blood pressure, daily urinary output, signs of
central nervous system, respiration distress (sign of severe
edema), etc. As soon as there was an abnormal finding, the
patient was classified as severe type, and termination of
pregnancy was indicated to save the fetus and the parturient.
Similarly, when pregnancy was complicated with SLE, in
addition to nephropathy, the obstetrician had to take great care
regarding the status of lupus activity in order to modify the
treatment regimen in those cases with flare-up, relapse, or
deterioration. The lupus activity index, the University of
Toronto SLE disease activity index score, and the physician's
global assessment were at the time used for monitoring lupus
activity during pregnancy. However, they were complicated to
use. Also, there was not enough time to adjust the treatment
regimen if lupus activity had relapsed or deteriorated, espe-
cially in the second half of pregnancy. Therefore, in this study,
we simplified the manner of assessing lupus activity during
pregnancy to be just like that for preeclampsia. If there were
abnormal findings, including blood tests, symptoms, and signs,
flare-up or deterioration should be considered and modifica-
tion of the treatment regimen had to be done as soon as
possible. With a simple assessment method for lupus activity
and quick modification of treatment regimen, better pregnancy
outcomes were achieved in this study.
Issues concerning the dosage of medications needed during
pregnancy have been raised. Azathioprine (imuran) and
chloroquine had been regarded as teratogens to the fetus,
resulting in their discontinued use during pregnancy, at least
during the first trimester. However, the safety of using imuran
and hydroxychloroquine (plaquenil) during pregnancies is
well documented.11e14 Therefore, not only the usage but also
the dosage of these immunosuppressive agents needed to be
maintained, even though the lupus activity was in remission
during pregnancy. By contrast, increase of the dosage or
adjuvant therapy was required if there was lupus relapse or
exacerbation during pregnancy.
There were four cases of SLE with first onset during
pregnancy found in this study, and they were classified as a
preconceptional unstable group with deterioration of lupus
activity during pregnancy. Except for one case that was found
during the first trimester, the other three pregnancies were first
complicated with SLE during the second trimester. In addition
to steroids, immunosuppressive agents, such as imuran and
plaquenil, were used as soon as the diagnosis of SLE had been
given. Although two of the patients suffered from pre-
eclampsia, all four pregnancies resulted in favorable outcomes
after the lupus was under good control.15 Based on the expe-
riences with these four cases, we found that the first onset of
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outcome could be achieved after good medical care was pro-
vided. In addition, unless there was a specific indication, such
as acute pulmonary edema due to heart failure, or renal failure,
termination of pregnancy was not necessary.
Pregnancy complications such as abortion, preterm labor, and
birth,16 intrauterine fetal death, preeclampsia, eclampsia, and
intrauterine fetal growth restriction, are commonly seen in
pregnancies complicated with SLE. Preterm birth (gestational
age<37 weeks) had been found to be associated with the disease
activity by Clark et al.16 In this study, we also noted the impor-
tance of lupus activity associated with the length of gestation
either preconceptionally or during pregnancy. In addition, sig-
nificant differences were found in newborn weight, related either
to the preconceptional lupus activity (t test, 2940 g vs. 2448 g,
p ¼ 0.002, 95% CI ¼ 792, 192) or to the disease activity
during pregnancy (t test, 2978 g vs. 2142 g, p < 0.001, 95%
CI ¼ 1137, 536). High incidence of pregnancy-induced
hypertension (12/60, 20%) was found in this series, but there
was no significant difference associated with the disease activity.
However, the number of pregnancies free from complications
(22/60, 36.7%), was significantly greater in the group with
remission of lupus activity than in that without remission, either
preconceptionally (17/34 vs. 5/21, by c2 test, p ¼ 0.014,
OR¼ 0.238, 95%CI¼ 0.073, 0.778) or during pregnancy (20/43
vs. 2/17, by c2 test, p ¼ 0.012, OR ¼ 0.153, 95% CI ¼ 0.031,
0.754). In addition, preterm birth, chronic hypertension, IUGR,
and renal failure were also correlated to the lupus activity either
preconceptionally or during pregnancy.
The use of steroids during pregnancy had been regarded as
the etiology of gestational diabetes mellitus. There were only
three cases that suffered from GDM in this series. The number
was too small to evaluate the interrelationships. The dosage
and the duration of steroids used might be related to this
gestational complication. However, a larger series is needed to
draw a conclusion.
In conclusion, women suffering from SLE are no longer
contraindicated for pregnancy unless they have not achieved a
good control of lupus activity or have poor renal function. With
adjuvant therapy with azathioprine and hydroxychloroquine,
the lowest effective dose of steroids is advocated for good
preconceptional control to avoid pregnancy complications. In
addition, maintenance of treatment regimen and close follow-
up with stringent monitoring of the lupus activity prenatally
are the only ways to gain favorable pregnancy outcome.Acknowledgments
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